Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Authors:

Abstract
No abstract available
Funding Information
  • Novartis Pharma
  • Merck Sharp and Dohme United Kingdom
  • Bristol-Myers Squibb
  • Taiho Pharmaceutical
  • Eisai
  • Novartis

This publication has 30 references indexed in Scilit: